苏帕
生物标志物
医学
卵巢癌
纤溶酶原激活剂
卵巢肿瘤
内科学
肿瘤科
恶性肿瘤
癌症
尿激酶受体
病理
胃肠病学
生物
生物化学
作者
Pia Leandersson,Grigorios Kalapotharakos,Emir Henić,Henrik Borgfeldt,Max Petzold,Gunilla Høyer‐Hansen,Christer Borgfeldt
出处
期刊:PubMed
日期:2016-03-01
卷期号:36 (3): 957-65
被引量:9
摘要
To assess preoperative blood levels of a biomarker panel in relation to the new classification system of epithelial ovarian cancer (EOC) type I and II.Preoperative plasma levels of B7-family protein homolog 4 (B7-H4), intact and cleaved soluble urokinase plasminogen activator receptor (suPAR), human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) were analyzed in 350 patients with adnexal lesions.The levels of suPAR(II-III), HE4, CA125 were all higher in EOC II than in EOC I, borderline and benign ovarian tumors. B7-H4 was increased in EOC II compared with benign ovarian tumors. The combination of suPAR(II-III), HE4, CA125 and age in premenopausal women discriminates EOC and borderline tumors from benign tumors to higher accuracy compared to the Risk of Ovarian Malignancy Algorithm (p=0.007).The biomarker panel suPAR(II-III), HE4, CA125 and age in premenopausal women improved discrimination of malignant and benign ovarian tumors. The plasma levels of B7-H4 were increased in patients with EOC II compared to those with benign ovarian tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI